Gayatri Sukumaran
Research Subjects
Gayatri Sukumaran has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Vasundra Lourdu
Sri Ramachandra Faculty of Pharmacy, SRIHER (DU), Chennai. Tamil Nadu, India
2 shared publications Angel Seslin Monica
Sri Ramachandra Faculty of Pharmacy, SRIHER(DU), Porur, Chennai-600116, Tamil Nadu, India
1 shared publication- Arghadip Das
Centre for Toxicology and Developmental Research (CEFTE), Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu 600116, India
1 shared publication C Uma Maheswara Reddy
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sri Ramachandra University, Porur, Chennai, India
1 shared publicationK Chitra
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sri Ramachandra University, Porur, Chennai, India
1 shared publication- Karthik Rajendran
Bioanalytical and Analytical, Scitus Pharma Services Private Ltd, Thirumazhisai-600124, Tamil Nadu, India
1 shared publication
Latest Publications
- Open Access
- 28 February 2026
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 1 (42) , 87-94
Seladelpar As a PPAR-δ Agonist in PBC: Pharmacological Insights and Clinical Applications
Primary biliary cholangitis (PBC) is an autoimmune disease that is characterized by the continuous destruction of small bile ducts within the liver, primarily affecting women aged 40-65. The condition leads to cholestasis and potential liver failure, necessitating effective treatment strategies. Seladelpar (MBX-8025) is a novel selective peroxisome proliferator-activated receptor (PPAR)-delta agonist that has been pioneered to address the unmet need in PBC management. Recent trials demonstrate that seladelpar significantly reduces alkaline phosphatase (ALP) levels and improves patients overall biochemical response, particularly in those intolerant or nonresponsive to UDCA. Particularly, seladelpar regulates bile acid metabolism via suppression of CYP7A1 and elevation of FGF21, contributing to its anti-inflammatory and antifibrotic actions. As a promising experimental drug, seladelpar could reshape treatment approach for PBC, providing an alternative treatment for patients who do not respond adequately to existing therapies due to inadequate responses.
- 28 February 2026
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 1 (42) , 87-94
Open AccessSeladelpar As a PPAR-δ Agonist in PBC: Pharmacological Insights and Clinical Applications
Primary biliary cholangitis (PBC) is an autoimmune disease that is characterized by the continuous destruction of small bile ducts within the liver, primarily affecting women aged 40-65. The condition leads to cholestasis and potential liver failure, necessitating effective treatment strategies. Seladelpar (MBX-8025) is a novel selective peroxisome proliferator-activated receptor (PPAR)-delta agonist that has been pioneered to address the unmet need in PBC management. Recent trials demonstrate that seladelpar significantly reduces alkaline phosphatase (ALP) levels and improves patients overall biochemical response, particularly in those intolerant or nonresponsive to UDCA. Particularly, seladelpar regulates bile acid metabolism via suppression of CYP7A1 and elevation of FGF21, contributing to its anti-inflammatory and antifibrotic actions. As a promising experimental drug, seladelpar could reshape treatment approach for PBC, providing an alternative treatment for patients who do not respond adequately to existing therapies due to inadequate responses.
- Open Access
- 11 December 2025
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 26 (1)
GB5, a synergistic phytotherapy for type 2 diabetes mellitus management: an integrated polyherbal approach from phytochemical profiling to network pharmacology
Background: Type 2 diabetes mellitus (T2DM) remains a global health burden characterized by insulin resistance, persistent hyperglycaemia, and chronic inflammation. Although single-target therapies effectively reduce glucose levels, they seldom address oxidative stress or adipocyte dysfunction. Polyherbal formulations (PHFs) harness synergistic phytochemicals for multimodal intervention; however, many lack mechanistic transparency owing to excessive inclusion of diverse botanical bioactives, suffer from non-standardized composition, and underexplore volatile antidiabetic constituents. Confronting these challenges, we developed Gluco Balance V (GB5), a cold-percolated ethanolic extract comprising equal proportions of bio-effective parts of Asparagus racemosus , Cyperus rotundus , Tinospora cordifolia , Terminalia arjuna , and Mimosa pudica . These botanicals were selected for complementary antidiabetic, antioxidant, and adiporegulatory activities documented in preclinical and clinical settings, indicating balanced, synergistic, and safe bioactivity. Methods: GB5’s phytochemical composition was standardized using gas chromatography–mass spectrometry (GC–MS) fingerprinting. In vitro assays assessed 2,2-diphenyl-1-picrylhydrazyl (DPPH) and nitric oxide (NO) scavenging capacity, inhibition of carbohydrate-digesting enzymes (α-amylase, α-glucosidase), enzyme kinetics, and effects on glucose uptake (GU) and lipid accumulation (LA) in yeast and 3T3-L1 adipocytes. Computational network pharmacology, molecular docking, and pharmacokinetic analyses elucidated molecular targets and bioavailability. Statistical analyses employed robust dose-response modelling, analysis of variance with Dunnett’s T3 test, and t-tests with false discovery rate correction. Results: GC–MS identified 21 bioactive compounds, including phytol, fatty acids, and sterols, driving GB5’s therapeutic synergy. GB5 showed robust antioxidant activity (DPPH and NO; half-maximal inhibitory concentration (IC 50 ) 88.6 and 74.8 µg/mL) and mixed-type inhibition of α-amylase and α-glucosidase (IC 50 71.6 and 174 µg/mL). At sub-inhibitory doses, it outperformed ascorbic acid (ASA) and acarbose. In 3T3-L1 adipocytes, GB5 increased GU by 32.3% at 2.0 mg/mL, comparable to rosiglitazone, and reduced lipid accumulation by 18.6% (90% effective concentration (EC 90 ) 0.742 mg/mL). Network pharmacology and molecular docking implicated peroxisome proliferator-activated receptor gamma (PPARγ), protein tyrosine phosphatase 1B (PTP1B), cyclooxygenase-2 (COX-2), and advanced glycation end-products–receptor for advanced glycation end-products (AGE–RAGE) pathways with 9,12-octadecadienoic acid and cholestan-3-ol, 2-methylene-, (3β,5α)- as key associates. Conclusions: GB5’s multi-targeted efficacy against hyperglycaemia, oxidative stress, and adipocyte dysfunction positions it as a promising complementary therapy for T2DM, meriting further in vivo evaluation. Graphical
- 11 December 2025
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 26 (1)
Open AccessGB5, a synergistic phytotherapy for type 2 diabetes mellitus management: an integrated polyherbal approach from phytochemical profiling to network pharmacology
Background: Type 2 diabetes mellitus (T2DM) remains a global health burden characterized by insulin resistance, persistent hyperglycaemia, and chronic inflammation. Although single-target therapies effectively reduce glucose levels, they seldom address oxidative stress or adipocyte dysfunction. Polyherbal formulations (PHFs) harness synergistic phytochemicals for multimodal intervention; however, many lack mechanistic transparency owing to excessive inclusion of diverse botanical bioactives, suffer from non-standardized composition, and underexplore volatile antidiabetic constituents. Confronting these challenges, we developed Gluco Balance V (GB5), a cold-percolated ethanolic extract comprising equal proportions of bio-effective parts of Asparagus racemosus , Cyperus rotundus , Tinospora cordifolia , Terminalia arjuna , and Mimosa pudica . These botanicals were selected for complementary antidiabetic, antioxidant, and adiporegulatory activities documented in preclinical and clinical settings, indicating balanced, synergistic, and safe bioactivity. Methods: GB5’s phytochemical composition was standardized using gas chromatography–mass spectrometry (GC–MS) fingerprinting. In vitro assays assessed 2,2-diphenyl-1-picrylhydrazyl (DPPH) and nitric oxide (NO) scavenging capacity, inhibition of carbohydrate-digesting enzymes (α-amylase, α-glucosidase), enzyme kinetics, and effects on glucose uptake (GU) and lipid accumulation (LA) in yeast and 3T3-L1 adipocytes. Computational network pharmacology, molecular docking, and pharmacokinetic analyses elucidated molecular targets and bioavailability. Statistical analyses employed robust dose-response modelling, analysis of variance with Dunnett’s T3 test, and t-tests with false discovery rate correction. Results: GC–MS identified 21 bioactive compounds, including phytol, fatty acids, and sterols, driving GB5’s therapeutic synergy. GB5 showed robust antioxidant activity (DPPH and NO; half-maximal inhibitory concentration (IC 50 ) 88.6 and 74.8 µg/mL) and mixed-type inhibition of α-amylase and α-glucosidase (IC 50 71.6 and 174 µg/mL). At sub-inhibitory doses, it outperformed ascorbic acid (ASA) and acarbose. In 3T3-L1 adipocytes, GB5 increased GU by 32.3% at 2.0 mg/mL, comparable to rosiglitazone, and reduced lipid accumulation by 18.6% (90% effective concentration (EC 90 ) 0.742 mg/mL). Network pharmacology and molecular docking implicated peroxisome proliferator-activated receptor gamma (PPARγ), protein tyrosine phosphatase 1B (PTP1B), cyclooxygenase-2 (COX-2), and advanced glycation end-products–receptor for advanced glycation end-products (AGE–RAGE) pathways with 9,12-octadecadienoic acid and cholestan-3-ol, 2-methylene-, (3β,5α)- as key associates. Conclusions: GB5’s multi-targeted efficacy against hyperglycaemia, oxidative stress, and adipocyte dysfunction positions it as a promising complementary therapy for T2DM, meriting further in vivo evaluation. Graphical
- Open Access
- 7 November 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 381-387
OPTIMIZATION AND VALIDATION OF ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY COUPLED WITH TANDEM MASS SPECTROMETRY FOR QUANTIFICATION OF EFAVIRENZ IN HUMAN PLASMA
Objective: This study presents the optimization and validation of a sensitive, rapid, and reliable ultra-performance liquid chromatography method for the quantification of efavirenz in human plasma, using efavirenz 13C6 as the internal standard. Method: The liquid-phase extraction technique was used to isolate the internal standard and the analyte from human plasma. The extracted samples were analyzed using chromatography on an Acentis® Express 90 Å C18 column (5 cm x 4.6 mm, 2.7µm), elution carried out using a mixture of ammonium acetate buffer (5 mmol) and acetonitrile as the mobile phase (70:30). The flow rate was maintained at 0.6 ml/min with an injection volume of 5 µl. The ionization mode was negative ion electrospray, with a source energy of 150 °C. Results: The linearity of the method was confirmed by a correlation coefficient of 0.9979, and the calibration range for efavirenz was found to be 50.00-5000 ng/ml. The precision and accuracy for both intra-day and inter-day measurements showed a %CV of less than 2.3% which is within the acceptable limit. The total run time was 3 min. The mean percentage recovery was 83.9 %. Conclusion: The developed method offers a significantly reduced run time, enhancing analytical throughput and efficiency compared to previously reported methods with longer durations. This makes it particularly suitable for high-throughput analysis in routine quality control or pharmacokinetic studies.
- 7 November 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 381-387
Open AccessOPTIMIZATION AND VALIDATION OF ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY COUPLED WITH TANDEM MASS SPECTROMETRY FOR QUANTIFICATION OF EFAVIRENZ IN HUMAN PLASMA
Objective: This study presents the optimization and validation of a sensitive, rapid, and reliable ultra-performance liquid chromatography method for the quantification of efavirenz in human plasma, using efavirenz 13C6 as the internal standard. Method: The liquid-phase extraction technique was used to isolate the internal standard and the analyte from human plasma. The extracted samples were analyzed using chromatography on an Acentis® Express 90 Å C18 column (5 cm x 4.6 mm, 2.7µm), elution carried out using a mixture of ammonium acetate buffer (5 mmol) and acetonitrile as the mobile phase (70:30). The flow rate was maintained at 0.6 ml/min with an injection volume of 5 µl. The ionization mode was negative ion electrospray, with a source energy of 150 °C. Results: The linearity of the method was confirmed by a correlation coefficient of 0.9979, and the calibration range for efavirenz was found to be 50.00-5000 ng/ml. The precision and accuracy for both intra-day and inter-day measurements showed a %CV of less than 2.3% which is within the acceptable limit. The total run time was 3 min. The mean percentage recovery was 83.9 %. Conclusion: The developed method offers a significantly reduced run time, enhancing analytical throughput and efficiency compared to previously reported methods with longer durations. This makes it particularly suitable for high-throughput analysis in routine quality control or pharmacokinetic studies.
- 1 January 2022
- Published by Indian Pharmaceutical Association - IPA in Indian Journal of Pharmaceutical Sciences
- Vol. 84 (1) , 228-231
Estimation of Pramipexole Dihydrochloride in Tablet Formulation by the Developed Reverse Phase High Performance Liquid Chromatography Method and its Validation
A simple, rapid isocratic reverse phase high performance liquid chromatography method was developed and validated for the determination of pramipexole dihydrochloride in tablet dosage form as per International Council on Harmonisation guidelines. In this method the chromatographic separation was carried out using C18 column with ultraviolet detector set at 264 nm. The eluent consisted of acetonitrile:phosphate buffer (pH 4.0) (70:30 by volume) with a flow rate of 1 ml/min. The method showed linear response with the retention time of 2.28 min. The main advantage of the developed method is its cost effectiveness and shortened run time. Hence this method can be applied for routine analysis of pramipexole in pharmaceutical dosage form.
- 1 January 2022
- Published by Indian Pharmaceutical Association - IPA in Indian Journal of Pharmaceutical Sciences
- Vol. 84 (1) , 228-231
Estimation of Pramipexole Dihydrochloride in Tablet Formulation by the Developed Reverse Phase High Performance Liquid Chromatography Method and its Validation
A simple, rapid isocratic reverse phase high performance liquid chromatography method was developed and validated for the determination of pramipexole dihydrochloride in tablet dosage form as per International Council on Harmonisation guidelines. In this method the chromatographic separation was carried out using C18 column with ultraviolet detector set at 264 nm. The eluent consisted of acetonitrile:phosphate buffer (pH 4.0) (70:30 by volume) with a flow rate of 1 ml/min. The method showed linear response with the retention time of 2.28 min. The main advantage of the developed method is its cost effectiveness and shortened run time. Hence this method can be applied for routine analysis of pramipexole in pharmaceutical dosage form.
- Open Access
- 1 January 2016
- Published by Manuscript Technomedia LLP in Pharmacognosy Research
- Vol. 8 (1) , 61-5
Isolation and Characterization of Chemopreventive agent from Sphaeranthus amaranthoides Burm F
Objective: To investigate the in vitro cytotoxic effect and to isolate and characterize a chemopreventive secondary metabolite from Sphaeranthus amaranthoides Burm F (sivakaranthai). Materials and Methods: In vitro cytotoxic effect was carried out by 3 (4,5-dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide assay. Different concentrations of the extracts were tested on three different cell lines namely A549, HT29, and MCF7. The chloroform extract was subjected to column chromatography, and the isolated compound was characterized by various spectral methods and by single crystal X-ray crystallography. Results: The concentration that cause 50% growth inhibition value of chloroform extract was found to be 0.9 and 19 μg/mL against MCF7 and A549 cell lines, respectively. Chloroform extract was subjected to column chromatography for the isolation of phytoconstituent. The structure of the isolated compound was identified by spectroscopic techniques such as infrared, nuclear magnetic resonance, XRD, and mass spectroscopy. On comparison of complete spectral detail of the compound, the proposed structure was identified as chrysosplenol D (a flavonoid). Chrysosplenol D was isolated for the first time from this plant. Conclusion: The chloroform extract had higher cytotoxic effect, and the isolated chrysosplenol D may be responsible for the anti-proliferative effect of the plant.
- 1 January 2016
- Published by Manuscript Technomedia LLP in Pharmacognosy Research
- Vol. 8 (1) , 61-5
Open AccessIsolation and Characterization of Chemopreventive agent from Sphaeranthus amaranthoides Burm F
Objective: To investigate the in vitro cytotoxic effect and to isolate and characterize a chemopreventive secondary metabolite from Sphaeranthus amaranthoides Burm F (sivakaranthai). Materials and Methods: In vitro cytotoxic effect was carried out by 3 (4,5-dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide assay. Different concentrations of the extracts were tested on three different cell lines namely A549, HT29, and MCF7. The chloroform extract was subjected to column chromatography, and the isolated compound was characterized by various spectral methods and by single crystal X-ray crystallography. Results: The concentration that cause 50% growth inhibition value of chloroform extract was found to be 0.9 and 19 μg/mL against MCF7 and A549 cell lines, respectively. Chloroform extract was subjected to column chromatography for the isolation of phytoconstituent. The structure of the isolated compound was identified by spectroscopic techniques such as infrared, nuclear magnetic resonance, XRD, and mass spectroscopy. On comparison of complete spectral detail of the compound, the proposed structure was identified as chrysosplenol D (a flavonoid). Chrysosplenol D was isolated for the first time from this plant. Conclusion: The chloroform extract had higher cytotoxic effect, and the isolated chrysosplenol D may be responsible for the anti-proliferative effect of the plant.